Evidence map›Paper›PMID 39694815›Full record

ArticleBriefings in bioinformatics2024

Synthetic plasma pool cohort correction for affinity-based proteomics datasets allows multiple study comparison.

Dries Heylen, Murih Pusparum, Jurgis Kuliesius, Jim Wilson, Young-Chan Park, Jacek Jamiołkowski, Valentino D'Onofrio, Dirk Valkenborg, Jan Aerts, Gökhan Ertaylan and 1 more

Erratum issuedAbstract readComparative Study
In one paragraph

Article in Briefings in bioinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Dries HeylenData Science Institute, Theory Lab, Hasselt University, 3590 Diepenbeek, Belgium.ORCID 0000-0001-7112-9651
Murih PusparumFlemish Institute for Technological Research (VITO), Mol, Belgium.ORCID 0000-0001-9560-0612
Jurgis KuliesiusCentre for Global Health Research, University of Edinburgh, Edinburgh BioQuarter, Edinburgh EH16 4UX, United Kingdom.
Jim WilsonCentre for Global Health Research, University of Edinburgh, Edinburgh BioQuarter, Edinburgh EH16 4UX, United Kingdom.
Young-Chan ParkInstitute of Translational Genomics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
Jacek JamiołkowskiDepartment of Population Medicine and Lifestyle Diseases Prevention, Medical University of Bialystok, 15-089 Białystok, Poland.
Valentino D'OnofrioCenter for Vaccinology, Ghent University and Ghent University Hospital, 9000 Ghent, Belgium.ORCID 0000-0003-3828-0442
Dirk ValkenborgHasselt University, Data Science Institute, 3590 Diepenbeek, Belgium.ORCID 0000-0002-1877-3496
Jan AertsAugmented Intelligence for Data Analytics (AIDA) Lab Department of Biosystems KU Leuven, Leuven, Belgium.ORCID 0000-0002-6416-2717
Gökhan ErtaylanFlemish Institute for Technological Research (VITO), Mol, Belgium.ORCID 0000-0001-5602-6435
Jef HooyberghsData Science Institute, Theory Lab, Hasselt University, 3590 Diepenbeek, Belgium.ORCID 0000-0003-3781-9645

Funding

Hasselt University BOF BOF20OWB29
6 · The paper itself

Abstract

Proteomics stands as the crucial link between genomics and human diseases. Quantitative proteomics provides detailed insights into protein levels, enabling differentiation between distinct phenotypes. OLINK, a biotechnology company from Uppsala, Sweden, offers a targeted, affinity-based protein measurement method called Target 96, which has become prominent in the field of proteomics. The SCALLOP consortium, for instance, contains data from over 70.000 individuals across 45 independent cohort studies, all sampled by OLINK. However, when independent cohorts want to collaborate and quantitatively compare their target 96 protein values, it is currently advised to include 'identical biological bridging' samples in each sampling run to perform a reference sample normalization, correcting technical variations across measurements. Such a 'biological bridging sample' approach requires each of the involved cohorts to resend their biological bridging samples to OLINK to run them all together, which is logistically challenging, costly and time-consuming. Hence alternatives are searched and an evaluation of the current state of the art exposes the need for a more robust method that allows all OLINK Target 96 studies to compare proteomics data accurately and cost-efficiently. To meet these goals we developed the Synthetic Plasma Pool Cohort Correction, the 'SPOC correction' approach, based on the use of an OLINK-composed synthetic plasma sample. The method can easily be implemented in a federated data-sharing context which is illustrated on a sepsis use case.

Indexed as

ProteomicsBlood ProteinsCohort StudiesDatabases, ProteinHumansBlood Proteinsbiomarkersnormalizationprotein quantificationproteomics

Identifiers

PMID39694815
PMCPMC11653412

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.